Top Markets
#1 Akedo Akedo +114.63%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.38%
#4 Cross Cross +37.46%
#5 Black Phoenix Black Phoenix +34.01%
#6 Velvet Velvet +33.97%
#7 OVERTAKE OVERTAKE +18.40%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.68%
#9 QANplatform QANplatform +14.56%
#10 Illuvium Illuvium +12.98%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
BNB Plus Corp. BNB Plus Corp.

BNB Plus Corp.

BNBX
Rank in Stocks #38647
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a... BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Share Price
$0.09
Last synced: 2026-07-28
Market Cap
$876.21K
Change (1 day)
0.00%
Change (1 year)
-97.79%
Country
US
Trade BNB Plus Corp. (BNBX)

Category

Healthcare
P/E ratio for BNB Plus Corp. (BNBX)
P/E ratio as of 2026 TTM: 0
According to BNB Plus Corp. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for BNB Plus Corp. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.